Protagonist Therapeutics Files 2025 Proxy Statement
Ticker: PTGX · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1377121
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Protagonist Therapeutics DEF 14A filed. Vote on exec pay & board at June 20 meeting.
AI Summary
Protagonist Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 20, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key details regarding director nominations and auditor ratification are expected to be presented.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing that provides information to shareholders and does not contain new material financial or operational news.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- 0001104659-25-041206 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- 20250620 (date) — Meeting Date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information regarding the company's annual meeting, including proposals to be voted on, director nominations, and executive compensation details.
When is the scheduled date for Protagonist Therapeutics' annual meeting?
The annual meeting for Protagonist Therapeutics, Inc. is scheduled for June 20, 2025.
Who is the filer of this proxy statement?
The filer of this proxy statement is Protagonist Therapeutics, Inc., as indicated by 'Registrant'.
What is the company's primary industry classification?
Protagonist Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Protagonist Therapeutics, Inc (PTGX).